Pro Medicus Limited (OTCMKTS:PMCUF – Get Free Report) shares shot up 10.9% on Thursday. The stock traded as high as $129.00 and last traded at $129.00. 70 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 587 shares. The stock had previously closed at $116.33.
Analyst Ratings Changes
Separately, Jefferies Financial Group downgraded shares of Pro Medicus from a “buy” rating to a “hold” rating in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $155.00.
Get Our Latest Stock Analysis on Pro Medicus
Pro Medicus Price Performance
The stock has a 50-day simple moving average of $120.47 and a 200 day simple moving average of $114.54.
About Pro Medicus
Pro Medicus Limited is an Australian medical technology company that develops software for medical imaging and healthcare organizations. Its solutions are designed to help hospitals, radiology practices and other providers store, manage, view and distribute medical images and related clinical information.
The company’s principal platform is Visage 7, an enterprise imaging system developed and commercialized through its wholly owned subsidiary, Visage Imaging. The platform supports the review of diagnostic studies such as computed tomography, magnetic resonance imaging and other medical images, with an emphasis on enterprise-wide access, workflow efficiency and advanced visualization.
Founded in 1983 and headquartered in Melbourne, Australia, Pro Medicus serves healthcare customers in Australia, North America and Europe.
See Also
- Five stocks we like better than Pro Medicus
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
- Chefs’ Warehouse Has Rallied 76%—Can the Stock Keep Climbing?
Receive News & Ratings for Pro Medicus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro Medicus and related companies with MarketBeat.com's FREE daily email newsletter.
